The PFKFB2 antibody is a crucial tool in studying the 6-phosphofructo-2-kinase/fructose-2.6-biphosphatase 2 (PFKFB2) protein, a member of the PFKFB enzyme family. PFKFB enzymes regulate glycolysis by controlling levels of fructose-2.6-bisphosphate (Fru-2.6-BP), a potent allosteric activator of phosphofructokinase-1 (PFK-1), a rate-limiting glycolytic enzyme. Unlike other isoforms (e.g., PFKFB3), PFKFB2 primarily functions as a kinase, promoting Fru-2.6-BP synthesis, but also exhibits phosphatase activity, balancing glycolytic flux. It is expressed in tissues like the liver, muscle, and heart, and plays roles in metabolic homeostasis, cell cycle regulation, and apoptosis.
PFKFB2 antibodies are widely used in research to detect protein expression, localization (cytoplasmic/nuclear), and post-translational modifications via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Studies highlight its involvement in diseases, particularly cancer, where altered PFKFB2 expression correlates with tumor progression and metabolic reprogramming. For example, elevated PFKFB2 in certain cancers may enhance glycolysis, supporting rapid proliferation. Conversely, its downregulation in others suggests context-dependent roles. The antibody’s specificity is validated using knockdown/knockout controls, ensuring reliable detection. Recent research also explores PFKFB2’s interaction with signaling pathways (e.g., AMPK, HIF-1α) and potential therapeutic targeting. Overall, PFKFB2 antibodies are vital for unraveling metabolic adaptations in health and disease.